Septerna, Inc. - SEPN STOCK NEWS

Septerna (NASDAQ: SEPN) has announced the discontinuation of its Phase 1 clinical trial for SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism treatment. The decision follows two severe cases of elevated unconjugated bilirubin in the multiple-ascending dose portion, though without liver enzyme elevations. The events were reversible, and no serious adverse events occurred.

Despite early signals of on-target pharmacological activity, the company is pivoting to advance multiple next-generation PTH1R agonists with different chemical structures. Septerna plans to select a new candidate for clinical trials later this year. The company is also proceeding with SEP-631, their MRGPRX2 modulator for mast cell diseases.

Financially, Septerna reports $137.5 million in cash and equivalents as of September 2024, plus $302.6 million from their October 2024 IPO, providing operational runway into at least second half of 2027.

Septerna (Nasdaq: SEPN) has appointed Gil Labrucherie as Chief Financial Officer. Labrucherie brings over 25 years of senior leadership experience in finance and legal roles within the biopharma and technology sectors. Most recently, he served as CFO and Chief Business Officer at ACELYRIN, and previously held executive positions at Nektar Therapeutics.

Throughout his career, Labrucherie has successfully raised more than $1.5 billion in private and public equity capital and generated over $1 billion in value from strategic partnerships. He will support Septerna's growth as the company advances its SEP-786 program and pipeline of oral small molecule GPCR programs, while expanding applications of its Native Complex Platform™.

Septerna, a clinical-stage biotech company focused on GPCR-targeted drug discovery, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jeffrey Finer, M.D., Ph.D., the company's CEO and co-founder, will deliver a presentation on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco. The presentation will be accessible via live webcast through Septerna's website and will remain available for 30 days afterward.

Septerna (SEPN) reported Q3 2024 financial results and business updates. The company recently initiated Phase 1 clinical trials for SEP-786, an oral treatment for hypoparathyroidism, with data expected in mid-2025. Following a successful IPO raising $302.6 million, Septerna has a strong cash position of $137.5 million as of September 30, 2024, expected to fund operations into H2 2027. Q3 financial results showed R&D expenses of $17.8 million, G&A expenses of $4.9 million, and a net loss of $20.5 million. The company is advancing multiple GPCR-targeted programs in endocrinology, immunology, inflammation, and metabolic diseases.

Septerna (Nasdaq: SEPN) has successfully completed its upsized initial public offering, raising $331.2 million in gross proceeds. The clinical-stage biotechnology company, focused on GPCR oral small molecule drug discovery, sold 18,400,000 shares at $18.00 per share, including 2,400,000 additional shares from the full exercise of underwriters' option. Trading began on the Nasdaq Global Market on October 25, 2024, under ticker SEPN. J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities served as joint bookrunners for the offering.

Septerna (Nasdaq: SEPN) has announced the pricing of its upsized initial public offering of 16,000,000 shares at $18.00 per share. The company has granted underwriters a 30-day option to purchase up to an additional 2,400,000 shares. Trading is expected to begin on the Nasdaq Global Market on October 25, 2024. The IPO's gross proceeds are anticipated to reach $288.0 million, before deducting underwriting discounts and commissions. The offering is expected to close on October 28, 2024, with J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities serving as joint bookrunners.